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A commentary on
A co-clinical approach identifies mecha-
nisms and potential therapies for andro-
gen deprivation resistance in prostate
cancer
by Lunardi A, Ala U, Epping MT, Salmena
L, Clohessy JG, Webster KA, et al.
(2013). Nat. Genet. 45, 747–755. doi:
10.1038/ng.2650
Prostate cancer is the second common
leading cause of cancer deaths in men
worldwide. Medical castration is the
standard-care treatment for metastatic
prostate cancer patients. Aggressive
prostate cancers have a progressive and
morbid disease process with a median
survival of 9–30 months (Nabhan et al.,
2011; Liu and Zhang, 2013). Androgen-
deprivation therapy (ADT) puts prostate
cancer in remission. Hormonal therapies
help in controlling advanced prostate can-
cers for some time and later on fail to
respond, evolve resistance mechanisms,
and undergo genetic deregulations with
poor patient survival rate and no cure.
As truly said, “Prevention is better than
cure” we look forward for tailoring new
treatment paradigms for the prevention
of castration-resistant prostate cancers
(CRPC).
Developing new, effective treatments
and understanding the genetic catastro-
phes behind CRPCs is very challenging.
Lunardi and team from Beth Israel
Deaconess Medical Center, Harvard
Medical School and other institutes
unveiled how a co-clinical strategy
comprising of a naturally occurring
hydroxybenzoquinone, Embelin which
is a small molecule X-linked inhibitor
of apoptosis (XIAP), in dual/triple com-
binations with MDV3100 an androgen
receptor (AR) antagonist, Bicalutamide an
antiandrogen (Casodex) or Dutasteride
a SRD5A1 (encoding 3-oxo-5-α-steroid
4-dehydrogenase 1) inhibitor and ADT
currently in clinical trials are the targets for
CRPC (Lunardi et al., 2013). Prostate can-
cers are characterized by distinct genetic
backgrounds which respond differentially
to ADT in mice and humans (Taylor
et al., 2010). Moving closer to find impor-
tant answers Lunardi et al. developed an
integrated human-mouse cross-species
genetic screening system which lead to
identification of the key molecular path-
ways and genetic alterations in response
to the standard therapeutics and new
biomarkers. They conducted an array-
based comparative genomic hybridization
which revealed the concomitant genetic
loss and mutation of PTEN and ZBTB7A
and TP53 stratifies with poor responsive-
ness to castration. The gene expression
arrays suggested downregulation of XAF1
(X-linked inhibitor of apoptosis protein–
associated factor-1), upregulation of
SRD5A1, relocalization of AR to the
nucleus and metastasis lead to poor sen-
sitivity to ADT. The genetic make-up
revealed the road-map of a powerful triple
combination therapeutic strategy to CRPC
patients genetically stratified by XAF1,
XIAP, and SRD5A1. The so-called genomic
triad with a co-clinical strategy is justified
(Figure 1).
Adverse reactions such as reproduc-
tive system and breast disorders, breast
tenderness, gastrointestinal disorders, hot
flushes, nausea, diarrhea, hepatic dis-
turbances (elevated transaminases levels
and jaundice), erectile dysfunction, sig-
nificant hypersensitivity reactions and
drug resistance has been reported with
antiandrogen agents like Bicalutamide,
Dutasteride and MDV3100 in clin-
ics (McLeod, 1997; Liu and Zhang,
2013). A small molecule quinone,
Embelin (2,5dihydroxy-3-undecyl-1,4
benzoquinone) the major active con-
stituent derived from the fruits (2.3%)
of Embelia species (local name; Vidanga)
has been known since antiquity in
the indigenous systems of medicine
well-documented for its antifertility,
potent antioxidant and anti-prostate can-
cer properties (Danquah et al., 2012;
Poojari, 2014). Embelin in combina-
tion with ionizing radiation exhibits
tumor suppression and angiogenesis
in hormone refractory prostate can-
cer resistant to radiation therapy (Dai
et al., 2008). The analysis of Embelin in
combination with the above indicated
antiandrogens- based approach is out-
standing. In the present study, human
prostate cancer cells VCaP, LNCaP, C4-2,
PC3, DU145, and castration-resistant
mouse models with concomitant loss of
PTEN-ZBTB7A and PTEN-TP53 were
used. A combination of Bicalutamide
(10mg/kg) and Embelin (60mg/kg) in
0.1% carboxymethyl cellulose oral admin-
istration daily for 5 days per week for
4 weeks were evaluated. Triple treat-
ment combinations with Bicalutamide
(10mg/kg), Embelin (60mg/kg) oral
dose for 3 days per week, Bicalutamide
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FIGURE 1 | A genomic triad with a co-clinical strategy targets for castrate-resistant prostate
cancer.
(10mg/kg) and Dutasteride (2mg/kg) oral
dose 2 days per week for four weeks
were also conducted. Embelin sensitized
the CRPCs to ADT via XAF1-XIAP path-
way, exhibited marked tumor regression
and potent reduction in the prolifera-
tion rate when treated in combination
with Bicalutamide in both PTEN and
ZBTB7A genotypes in CRPCs. Embelin
in combination with steroid-free medium
and MDV3100 triggered the apopto-
sis promotion. Also, double null for
PTEN and ZBTB7A, for PTEN and
TP53 as well as PTEN-null CRPCs with
SRD5A1 upregulation and, particularly
the tricombo power of Dutasteride fur-
ther significantly decreased the prostate
tumor burden in response to Embelin
treatment and ADT (Lunardi et al.,
2013).
In the era of personalized medicines
for cancer-care, there is a dire need to
focus on defining and treating cancer
by its genetic abnormalities. In the past
few decades, molecularly targeted ther-
apies for specific tumor mutations in
patients are in full swing. This meticulous
research analysis is exemplary for its con-
tribution in the field of prostate cancer
genetics-based novel therapeutic modal-
ity for overcoming castration resistance.
It illuminates the potency of quinonic
Embelin, a rich heritage of traditional
herbal medicine much unknown about
its novel “co-clinical genomics mix” for
the first time via the integrated cross-
species genetic approach system. The
abrogation of the XAF1/XIAP pathway
combined with SRD5A1 inhibition and
ADT, implicates this new signature in
designing and promotion of a natural
plant based drug-targeting therapeutics on
genetic mutations-driving biomarkers for
the treatment of CRPC. The power of
genomic triad with a co-clinical strategy
would revolutionalize into translational
human cancer therapy paving the way for
similar approaches to other cancers too.
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